Summary Four monoclonal antibodies (MAbs) specific for the extracellular domain of the human erbB-2/ HER2 protein (FRP5, FSP16, FWP51 and FSP77) have been isolated (Harwerth et al., J. Biol. Chem., 267, 15160-15167, 1992). In this paper we describe the effects of erbB-2 specific MAb administration on the tumorigenic growth of human erbB-2 transformed NIH3T3 cells implanted into The erbB-2 protein is a member of the receptor tyrosine kinase family and is closely related to the epidermal growth factor (EGF) receptor (Schechter et al., 1984; Coussens et al., 1985; Yamamoto et al., 1986) . The oncogenic potential of the erbB-2 receptor has been shown to be released through different mechanisms involving point mutation (Segatto et al., 1988; Suda et al., 1990 ) and overexpression. Amplification of the c-erbB-2 gene, leading to overexpression of the protein, has been observed in a high percentage of human breast and ovarian tumour cells (Slamon et al., 1987; Kraus et al., 1987; van de Vijver et al., 1987; Slamon et al., 1989) . It is likely that the elevated levels of the erbB-2 protein contribute to the malignancy process. Overexpression of erbB-2 in cultured cells has been found to induce the malignant phenotype in fibroblasts (Di Fiore et al., 1987) as well as in mammary epithelial cells (Pierce et al., 1991) . Overexpression of erbB-2 in breast and ovarian carcinomas has been correlated with an unfavourable patient prognosis (Slamon et al., 1987; Varley et al., 1987; Berger et al., 1988; Slamon et al., 1989; Wright et al., 1989) .
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth I.-M. Harwerth (Harwerth et al., J. Biol. Chem., 267, 15160-15167, 1992) . In this paper we describe the effects of erbB-2 specific MAb administration on the tumorigenic growth of human erbB-2 transformed NIH3T3 cells implanted into athymic nude mice. Two antibodies, FWP51 and FSP77, inhibited the onset of tumour growth, while the administration of FRP5 and FSP16 did not affect tumour growth. In addition, administration of MAbs FWP51 and FSP77 led to a retardation in the growth of established tumours. Treatment was not curative in that tumours regrew within two weeks of the final treatment. The administration of a combination of MAbs FWP51 and FSP77 which react with two distinct regions on the erbB-2 molecule was more effective than treatment with either MAb alone. The two growth-inhibitory antibodies were also effective in the treatment of tumours established from SKOV3 cells, a human ovarian tumour cell line with high levels of the erbB-2 protein. The effect of the MAbs on the anchorage-independent growth of erbB-2 transformed cells and on erbB-2 receptor turnover was also measured.
The erbB-2 protein is a member of the receptor tyrosine kinase family and is closely related to the epidermal growth factor (EGF) receptor (Schechter et al., 1984; Coussens et al., 1985; Yamamoto et al., 1986) . The oncogenic potential of the erbB-2 receptor has been shown to be released through different mechanisms involving point mutation (Segatto et al., 1988; Suda et al., 1990) and overexpression. Amplification of the c-erbB-2 gene, leading to overexpression of the protein, has been observed in a high percentage of human breast and ovarian tumour cells (Slamon et al., 1987; Kraus et al., 1987; van de Vijver et al., 1987; Slamon et al., 1989) . It is likely that the elevated levels of the erbB-2 protein contribute to the malignancy process. Overexpression of erbB-2 in cultured cells has been found to induce the malignant phenotype in fibroblasts (Di Fiore et al., 1987) as well as in mammary epithelial cells (Pierce et al., 1991) . Overexpression of erbB-2 in breast and ovarian carcinomas has been correlated with an unfavourable patient prognosis (Slamon et al., 1987; Varley et al., 1987; Berger et al., 1988; Slamon et al., 1989; Wright et al., 1989) .
The use of monoclonal antibodies (MAbs) in diagnosis and treatment of cancer has many promising aspects. The tumour enriched expression and extracellular accessibility of the erbB-2 receptor make it a potential target for immunotherapy. We have recently described several MAbs which bind to the extracellular domain of the human erbB-2 protein (Harwerth et al., 1992) . These MAbs are able to affect erbB-2 receptor phosphorylation and turnover, as well as the anchorage-dependent growth properties of erbB-2-expressing tumour cells. In this paper we describe the effect of these anti-erbB-2 monoclonal antibodies, alone and in combination, on the tumorigenic growth of erbB-2 expressing cells in athymic nude mice. Two of the MAbs, FWP51 and FSP77, inhibited the onset of tumour growth. The combination of both MAbs was more effective than individual antibody treatment. To correlate the in vivo anti-tumour activity of the antibodies with in vitro characteristics, individual antibodies and antibody combinations were tested in three assays:
Anchorage-independent growth of erbB-2 transformed cells, erbB-2 receptor tyrosine phosphorylation and receptor turnover following antibody treatment were measured. The results suggest that no individual parameter correlates completely with the anti-tumour activity of a MAb. In general, MAb induced reduction of the erbB-2 receptor level reflects best the in vivo anti-tumour activity.
Materials and methods
Cell lines, cell culture and transfection of NIH3T3 cells SKBR3 and SKOV3 are human breast and ovarian tumour cell lines, respectively, which exhibit overexpression of the erbB-2 protein due to erbB-2 gene amplification (Hynes et al., 1989; Marth et al., 1990) . Clone NIH3T3#3.7 is a mouse fibroblast cell line stably transfected with a plasmid expressing the activated human c-erbB-2 gene under control of the SV40 promoter (pSV2erbB-2(VE)) (Masuko et al., 1989) (Harwerth et al., 1992) . Their binding affinities were determined by ELISA as described (Wels et al., 1992a chain antibody-exotoxin A recombinant protein, scFv(FRP5)-ETA, was tested. The construction and expression of a gene encoding the chimeric protein and its purification and biological activity have been described previously (Wels et al., 1992b An athymic mouse model of the human ovarian tumour cell line SKOV3 was also tested. Approximately 25 mg of SKOV3 tumour tissue was s.c. implanted into three groups of five mice. Therapy was initiated 5 days post implantation when tumours had reached approximately 50 mm3 and was carried out for 10 days. The animals received a total amount of 0.5 mg of MAb FWP51 or MAb FSP77/mouse or PBS. Tumour growth was followed by measuring two perpendicular tumour diameters, the tumour volumes were calculated, and the data were statistically analysed as described (Meyer et al., 1989) .
Anchorage-independent growth assay Anchorage-independent growth was studied by examining the colony-forming capability of NIH3T3#3.7 cells suspended in soft-agar. Experiments were performed using 35 mm tissue culture dishes. A 1 ml cell-free feeder layer consisted of 0.8% agarose-DMEM supplemented with 6% FCS. The 1 ml overlayer contained 1 x 103 cells in 0.3% agarose-DMEM supplemented with 5% FCS and the MAbs (10 ig ml-'), which were only added to the top layer. To stain colonies 1 ml of PBS containing 0.5 mg ml-' nitro blue tetrazolium (Sigma) was added to the cultures on day 20. The next day colonies ) 0.2 mm were counted using an Artek Counter (Dynatech Laboratories, Inc.). The results from each experimental group represent the mean of triplicate samples.
Determination of the effect of the monoclonal antibodies on receptor turnover (downregulation assay) Subconfluent cultures of NIH3T3#3.7, SKOV3 and SKBR3 cells were metabolically labelled for 16 h in methionine-free DMEM containing 2% dialysed FCS and 50 pCi ml-' of [35S] methionine (Trans35Slabel, ICN Radiochemicals). Cells were chased with fresh medium in the absence or presence of 10jg ml-' of monoclonal antibodies for 3 h or 24 h and were extracted in lysis buffer as described previously (Harwerth et al., 1992) . The erbB-2 protein was immunoprecipitated from aliquots of lysate containing equal amounts of [35S] using the 21N antiserum (Hynes et al., 1989) . A mixture of the four erbB-2 specific monoclonal antibodies was used in order to immunoprecipitate only the transfected human erbB-2 protein from the NIH3T3#3.7 cell extracts. The gels were run and the bands quantitated as described.
tutively phosphorylated in both cases (Peles et al., 1991) . Thus, activation of erbB-2 by a point mutation should reflect the situation of human tumours overexpressing this receptor.
Following s.c. injection of NIH3T3#3.7 cells into athymic nude mice, rapidly growing tumours are formed with a short latency. Individual MAbs were i.v. injected into groups of five mice, on days 0 to 9 after s.c. inoculation of approximately 5 x 106 NIH3T3#3.7 cells. Figure 1 shows that the tumorigenic growth of NIH3T3#3.7 cells was significantly inhibited in nude mice injected with MAbs FWP51 and FSP77, when compared with control mice. Total inhibition was achieved during the period of MAb-treatment and the inhibitory effect persisted up to 12 days following the final injection. Afterwards the tumours began to grow rapidly. Thus treatment with the erbB-2 specific MAbs FWP51 and FSP77 significantly delayed the onset of tumour growth, but was not curative. In two separate experiments, MAb FSP77 was found to be more potent in tumour growth inhibition.
The two growth inhibitory MAbs recognise two distinct domains on the erbB-2 molecule as determined by competition experiments described previously (Harwerth et al., 1992) . The effect of treating tumour-bearing animals with a combination of FWP51 and FSP77 was examined. Figure 1 demonstrates that the combinatorial treatment was more effective than single antibody treatment. The tumours started to grow 15 days after the last MAb-injection.
Treatment of animals with MAbs FRP5 and FSP16 which compete with each other for erbB-2 binding (Harwerth et al., 1992) had no effect on the tumour growth of NIH3T3#3.7 cells (Figure 2a) . The lack of effect is not due to a trivial reason such as low affinity since the binding constants of all four MAbs are comparable (Table I ). In addition the isotype of FRP5 is the same as that of the growth inhibitory antibodies FWP51 and FSP77. MAbs FRP5 and FSP16 bind to a domain distinct from those recognised by MAbs FWP51 and FSP77. It is likely that antibody binding to different domains on the erbB-2 receptor can influence in vivo tumour growth. The effects of the erbB-2 specific monoclonal antibodies upon tumour growth Four monoclonal antibodies (FRP5, FSP16, FWP51 and FSP77), which specifically recognise the extracellular domain of the human erbB-2 receptor have recently been isolated and characterised (Harwerth et al., 1992) . The in vivo anti-tumour activity of the erbB-2 specific MAbs was tested in two models. The first model consists of NIH3T3 transfectants (NIH3T3#3.7) expressing an activated erbB-2 receptor, the second model is a human ovarian carcinoma cell line (SKOV3) with high levels of the normal erbB-2 protein.
Activation of the erbB-2 receptor by a point mutation or by overexpression is comparable in that the receptor is consti- It is possible to develop a cytotoxic reagent using MAb FRP5. We have recently described the isolation and characterisation of a recombinant single chain antibody-exotoxin A fusion protein, scFv(FRP5)-ETA. The antigen-binding domain of MAb FRP5 was fused to a truncated Pseudomonas exotoxin A. The scFv(FRP5)-ETA molecule inhibited the growth of human tumour xenografts in nude mice (Wels et al., 1992b) . Figure 2b shows the in vivo antitumour activity of the recombinant scFv(FRP5)-ETA molecule on NIH3T3#3.7 cells. 2 x 106 tumour cells were inoculated in nude mice on day 0. On the same day miniosmotic pumps which continuously delivered scFv(FRP5)-ETA at a rate of 6 1g/day were s.c. implanted into a group of five mice. The pumps delivered a constant amount of material for approximately 7 days. In the group that received the recombinant scFv(FRP5)-ETA there was minimal tumour growth up to day 21. In contrast to the treatment with MAb FRP5 which exhibited no effect on the onset of tumour growth, tumour growth was inhibited by 80% in animals which received 6 ,ug/day of scFv(FRP5)-ETA.
To examine the effect of the monoclonal antibodies on the tumorigenic growth of human cancer cells, SKOV3 ovarian tumour cells which express high levels of the erbB-2 protein were studied. The carcinoma cells grow as xenografts in nude mice and approximately 25 mg of SKOV3 tumour tissue were s.c. implanted into the flanks of three groups of five mice. The implants grew for 5 days to a size of approximately 50 mm3 and antibody treatment was begun by i.v. injection of 50 Lg/mouse/day of MAbs FWP51 or FSP77. Figure 3 demonstrates that during the 10 day treatment period MAbs FWP51 and FSP77 almost completely inhibited tumour growth. Once treatment was discontinued, tumour growth started 2-4 days later. The delay was slightly longer in animals which had received MAb FWP5 1.
The effects of the erbB-2 specific MAbs on the anchorage-independent growth of erbB-2 transformed cells We examined the effect of the erbB-2 specific antibodies and of the combination of FWP51 + FSP77 on the anchorageindependent growth of NIH3T3#3.7 cells. As depicted in Figure 4 the four MAbs had distinct effects on soft-agar colony formation. Of the two MAbs which showed in vivo inhibitory effects, only MAb FWP51 inhibited colony formation while MAb FSP77 was moderately stimulatory at the lowest dose tested (5-fold at 10 pg). MAbs FRP5 and FSP16, which did not have any significant effect on tumour growth, exerted a marked stimulatory effect on NIH3T3#3.7 cells. An 8 to 11 fold increase in the number of soft-agar colonies was observed. The effects of the MAbs on NIH3T3# 3.7 soft-agar colony formation were dose dependent. MAbs FRP5, FSP16 and FSP77 were most stimulatory at low doses. MAb FWP51 inhibited colony formation best at high doses (85% at 501g ml--'). A control IgG-antibody did not affect colony formation (data not shown). Another control showed that there was no stimulatory effect on anchorageindependent growth of pSV2neo expressing NIH3T3 fibroblasts following treatment with the erbB-2 specific MAbs (data not shown). Therefore, the effects of the antibody treatment are dependent upon the expression of the human erbB-2 receptor.
The effect of the monoclonal antibodies on the rate of receptor turnover The interaction of receptor tyrosine kinases with their ligands is coupled to rapid endocytosis. Monoclonal antibodies can induce an analogous effect on the rat neu receptor (Drebin et al., 1985;  Yarden, 1990 ) and on the human erbB-2 receptor (Hudziak et al., 1989; Stancovski et al., 1991; Harwerth et al., 1992) . It is likely that down-modulation results from the ability of divalent antibodies to cross-link cell surface receptors, which leads in turn to their internalisation. The effect of the erbB-2 specific antibodies on the turnover of the receptor in the NIH3T3#3.7, SKOV3 and SKBR3 cell lines was examined. The SKBR3 cell line, which was previously studied (Harwerth et al., 1992) Figure 5 . The turnover of the mutated erbB-2 receptor in NIH3T3#3.7 cells was more rapid than the turnover of the normal receptor in the two tumour cell lines reflecting the activated state of the mutated receptor (Bargmann & Weinberg, 1988; Yarden, 1990 (Hynes, 1993 and ref. therein) , including breast, ovaries, lung, stomach and salivary gland. The accessibility of this protein on the cell surface, and its implication in the development and malignancy of these tumours, especially breast carcinomas (Slamon et al., 1989) , make the erbB-2 receptor an attractive target for specific MAbs which may be useful in diagnosis and therapy. Several groups have raised erbB-2-specific monoclonal antibodies (Hudziak et al., 1989; McKenzie et al., 1989; Stancovski et al., 1991; Harwerth et al., 1992) . Results from immunohistochemical studies indicate that embryonic tissues contain the highest level of erbB-2 protein. In the adult expression is limited to certain epithelial cells (Press et al., 1990) . Therefore, monoclonal antibodies directed against the erbB-2 protein may be relatively specific in their targeting to tumours containing elevated levels of the protein. We have previously described the isolation and characterisation of four erbB-2 specific MAbs which bind to the extracellular domain of the receptor protein (Harwerth et al., 1992) . In the present study we have used two tumour models to address the potential of these antibodies as anti-tumour agents. Furthermore, we attempted to correlate the in vivo anti-tumour activities of the MAbs with their effects on cultured tumour cells and on the receptor itself.
The two tumour models tested were mouse fibroblasts transformed by an activated human erbB-2 protein, NIH3T3#3.7 cells, and human ovarian tumour cells, SKOV3, which display c-erbB-2 gene amplification and elevated levels of the erbB-2 protein. Activation of the erbB-2 receptor by a point mutation, as in the NIH3T3#3.7 cells, is comparable to the situation of an overexpressed erbB-2 receptor. Peles et al. (1991) (Harwerth et al., 1992) .
In an attempt to correlate the in vivo anti-tumour activity of MAbs FWP51 and FSP77 to an in vitro measurable activity, the effects of the MAbs on the anchorage-dependent and -independent growth of erbB-2 expressing tumour cells and on the erbB-2 receptor itself were characterised. A summary of these experiments, both those presented in this paper and in a previous publication (Harwerth et al., 1992) , is shown in Table II (Harwerth et al., 1992 Figure 5 . From these results we favour the idea that the combination of epitopes recognised by MAbs FWP51 and FSP77, and the reduction in the overall level of the erbB-2 protein both contribute to the anti-tumour activity of these antibodies.
The results show that treatment with anti-erbB-2 antibodies which bind to different domains of the receptor leads to potent in vivo anti-tumour effects. However, tumour growth inhibition by the antibodies was transitory. Once treatment was discontinued the tumours regrew. Therefore a more successful approach will likely involve the combination of a specific antibody with a potent effector function. erbB-2 specific MAbs, which were expressed as recombinant single chain antibody-toxin chimeric molecules (Wels et al., 1992b; Batra et al., 1992) , displayed cytotoxic anti-tumour activity. Short-term treatment with a low dose of scFv(FRP5)-ETA inhibited SKOV3 tumour cell growth by 96% (Wels et al., 1992b) 
